Fig. 1From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosisDecline of FVC per month during the administration period of pirfenidone and after switching to nintedanib. Only ten patients could perform lung function tests at 6 months after switching to nintedanib. However, in seven of ten patients (70%), nintedanib suppressed FVC decline compared with that during the administration period of pirfenidoneBack to article page